Tag Archive for: T-cell therapy

UPDATE: AB-3028 Reaches Clinical Trial Stage for mCRPC

AB-3028, programmable circuit T cell therapy for metastatic castration-resistant prostate cancer (mCRPC), has now advanced into a Phase 1/2 clinical trial. This marks the first clinical testing of this highly engineered, logic‑gated CAR-T platform in prostate cancer, moving it from a purely preclinical concept into human evaluation. The trial should start recruiting in January 2026. […]

Phase 1/2 Trial for MK-6070: A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers

MK-6070 is an engineered trispecific T-cell engager designed to target a protein called DLL3, which is predominantly found on certain aggressive neuroendocrine tumors, including prostate cancer. This molecule works by simultaneously binding to DLL3 on tumor cells, the CD3 receptor on T cells, and serum albumin, which extends the drug’s circulation time in the body. […]